RESEARCH ARTICLE

Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients

Dan Beziz‡, Sandrine Colas‡*, Cédric Collin, Rosemary Dray-Spira, Mahmoud Zureik

Department of Epidemiology of Health Products, Division for Science and European Strategy, French National Agency for Medicines and Health Products Safety (ANSM), Saint-Denis, France

‡ These authors are joint first authors on this work.
* sandrine.colas@ansm.sante.fr

Abstract

Background

Total hip replacement (THR) is successful in treating hip arthritis. Prosthetic survivorship may depend on the medications taken by the patient; particularly, the role of benzodiazepines and related drugs (Z-drugs) with THR revision has been poorly investigated. Our objective was to compare THR short-term survivorship according to level of exposure to benzodiazepine and Z-drugs.

Design, Setting and Participants

All French patients aged 40 years or older, having undergone primary THR from January 1, 2009, through December 31, 2012, for arthritis according to French national health insurance databases were included in the cohort. Outcome of interest was THR revision, including any surgical procedure in which the implant or any component was changed or removed. Follow-up started the day the primary THR was performed. Observations were right-censored on December 31, 2014, if neither revision nor death had yet occurred. Exposure of interest was the cumulative defined daily doses per day (cDDD/day) of benzodiazepines and Z-drugs dispensed within 6 months before or after inclusion. We defined four exposure groups; cDDD/d = 0: unexposed; <0.08: low exposure; 0.08–0.38: medium exposure; >0.38: high exposure. THR survivorship was assessed according to level of exposure to benzodiazepine and Z-drugs in univariate and multivariate Cox models adjusted for patient, THR and implanting center characteristics.

Results

The study cohort comprised 246,940 individuals: mean age at baseline, 69.9 years; women, 57.9%; unexposed: 51.7%; low exposure: 16.7%; medium exposure: 15.9%; and
high exposure: 15.7%. During the median 45-month follow-up, 9043 individuals underwent prosthetic revision. Adjusted hazard ratios in low, medium and high exposed groups were 1.18 (95%CI, 1.12–1.26; P<0.001), 1.32 (95%CI, 1.24–1.40; P<0.001) and 1.37 (95%CI, 1.29–1.45; P<0.001), respectively, compared to unexposed.

**Conclusion and Relevance**

Exposure to benzodiazepines and Z-drugs is associated with an increased risk of THR revision, with a dose-response relationship. Cautious prescribing might be needed as well as careful history examination and assessment of risk for patients with a hip prosthesis.

**Introduction**

Osteoarthritis, a degenerative cartilage disease, is a leading cause of disability worldwide in the elderly [1–3]. Total hip replacement (THR) to replace a damaged coxo-femoral joint, is one of the most common orthopaedic procedures for treating all-aetiology hip osteoarthritis [4]. Primary or secondary degenerative osteoarthritis is the main indication [5], but THR is also used to treat rheumatoid arthritis or avascular necrosis or after trauma, common in elderly women especially. THR prevalence has substantially increased in industrialized countries in recent decades, largely due to population ageing. Despite positive results, revision is sometimes necessary (approximately 1% per year). Prosthetic revision is longer and more complex than primary arthroplasty and has a higher incidence of postsurgical complications. Hence, understanding factors associated with prosthetic survivorship constitutes a public health issue.

BZDs and related drugs (Z-drugs) are the most widely-used drug classes [6]. Their pharmacological properties multiply therapeutic applications in anxiety, insomnia, epilepsy and muscle spasms. Their use is a matter of concern among world public health regulators due to the risks from both short and long-term exposure, particularly in elderly patients [7] where BZDs are often prescribed inappropriately [8]: although the long-term effectiveness of benzodiazepines remains unproved for insomnia and questionable for anxiety [9,10], chronic use is predominant in older people. Several studies showed that BZDs consumption in France is among the highest in Europe [11]. Consumption is not devoid of adverse effects: memory problems, daytime sedation, ataxia, increased risk of motor vehicle accidents and falls [8].

Although the association between BZDs exposure and increased risk of hip fracture leading to THR is well-documented [12–23], few researches studied the association with THR revision. The aim of this study was to examine the association between BZDs and Z-drugs exposure and THR short-term survivorship in a population-based cohort, using French health insurance system linked to hospital discharge databases [24–28].

**Material and Methods**

**Data Sources**

We used the French Health Insurance Information System (SNIIRAM), [24, 27–29], covering the entire French population, with different employment-based schemes. We only used the data for general scheme beneficiaries (approximately 77% of the population), for whom SNIIRAM records, with dates, outpatient drugs (Anatomical Therapeutic Classification codes), medical devices, services and procedures reimbursed. The database does not state medical indications per reimbursement but contains patients’ demographic, administrative, and medical
details (chronic conditions such as diabetes mellitus, cancer or cardiovascular disease) and date of death. An anonymous, unique patient identifier links SNIIRAM information to national hospital discharge databases (Programme de Médicalisation des Systèmes d’Information, PMSI), providing reasons for admission (using International Statistical Classification of Diseases, 10th Revision, ICD-10).

Inclusion and Exclusion Criteria
The eligible population was patients aged 40 years or older, having undergone unilateral primary THR for osteoarthritis from January 1, 2009, through December 31, 2012 (48 months). Patients having primary THR for trauma or bone cancer, prosthetic revision before the inclusion period, simultaneous bilateral THR, not being reimbursed 6 months after THR or with non-matching procedure in PMSI were excluded. The entire study cohort population of 249,597 patients was described. THR characteristics were missing for 2,657, excluded from subsequent analyses, leaving 246,940 (Fig 1); 61,054 were enrolled in 2009, 60,808 in 2010, 62,230 in 2011 and 62,848 in 2012.

Approval was obtained from the French data protection agency (Commission Nationale de l’Informatique et des Libertés). Informed consent was not required as information was collected anonymously.

Outcome and follow-up
Outcome was THR revision (including any surgical reintervention in which the implant or any components was changed or removed). Follow-up started at the date of primary THR. Observations were right-censored on December 31, 2014, if neither revision nor death had yet occurred. The minimum backward period was two years (maximum six years).

Variable of Interest: Exposure to benzodiazepines and Z-drugs
All common BZDs and two Z-drugs (Zopiclon, Zolpidem) referred to as “BZDs”, were exposure of interest. We identified patients prescribed BZDs six months before or after inclusion, as baseline time-window of interest, to have a sufficient period to accurately measure exposure around implantation.

The defined daily dose (DDD), recommended by the World Health Organization, is the average dose per day for a drug used in its primary indication in adults and a unit used for measuring a prescribed drug amount [30]. We calculated the sum of the BZDs and Z-drugs DDDs dispensed (all drugs combined) during the time window of interest, divided by 365 (days), to get a cumulative DDD per day (cDDD/d), as an exposure indicator. We then defined four exposure categories: three tertiles for exposed patients (Low = cDDD/d < 0.08; Medium = 0.08 ≤ cDDD/d ≤ 0.38; High = cDDD/d > 0.38) and the fourth category for unexposed.

Covariates
We collected a series of patient, implantation centre and THR characteristics known to be or suspected of being associated with a risk of post-arthroplasty complications. Patients’ age, sex and date of death, came from the SNIIRAM database.

At baseline, treatments were identified by prescriptions (Anatomical Therapeutic Classification codes) reimbursed at least once within 180 days before or after inclusion, antidepressants, antihypertensives, oral corticosteroids, osteoporosis treatments, psychostimulants, antiepileptics, anxiolytic or hypnotic non-benzodiazepines (non-BZD), antipsychotics. Diabetes mellitus, obesity, Parkinson’s disease, immunodeficiency and chronic kidney disease were defined.
The initial population was patients 40 years or older admitted to a French hospital (excluding overseas territories) and billed for total hip replacement (THR) components with coding a hip arthroplasty from January 1, 2009, through December 31, 2012. All health insurance schemes were combined. All patients received at least 1 health insurance reimbursement after the hospital stay for the implant procedure. PMSI stands for Programme de Médicalisation des Systèmes d’Information.

Fig 1. Study population flowchart.

doi:10.1371/journal.pone.0155783.g001

(ICD-10 categories) on the basis of hospital discharge reports or chronic condition recorded the year before inclusion with relevant prescriptions. The mean number of THR procedures per month (during the 4-years inclusion period) was calculated. Whether implantation centres were private or public and hospital stay (in days) were also collected.
Four types of THR fixation technique are available: uncemented, both-sides cemented, hybrid (femoral component cemented, acetabular component uncemented), and reverse hybrid (femoral component uncemented, acetabular component cemented). Four bearing couples were analyzed: ceramic-on-ceramic (CoC), ceramic-on-polyethylene (CoP), metal-on-metal (MoM) and metal-on-polyethylene (MoP) [31].

Statistical Analysis

Main Analyses. Continuous variables were not normally distributed and were categorized. Patient, centre, hospital stay and THR (cement, bearing surface) characteristics were compared according to cDDD/d group using a Chi-square test. Kaplan-Meier survival analysis and log-rank test were used to assess differences in cumulative revision risk according to cDDD/d group. Hazard ratios (HRs) for revision according to cDDD/d groups were assessed using univariate and multivariate Cox proportional hazards regression models, adjusting for possible confounding factors: sex; age at implantation: young (40–59), middle-aged (60–74) and elderly (≥75 years); diabetes mellitus; obesity; Parkinson’s disease; immunodeficiency; medication (antidepressants, oral corticosteroids, antiosteoporotics, psychostimulants, non-BZD antiepileptics, anxiolytic/hypnotic non-BZD, antipsychotics); public or private; centre activity volume (tertiles); stay (3 groups: <6; 6–12; >12 days); cement type (4 groups); and bearing surface (4 groups). These characteristics were included simultaneously in the multivariate Cox proportional hazards regression model. Assumption of proportional hazards was graphically assessed for each variable. Interactions between exposure and age, as well as sex, in association with prosthetic survivorship were investigated.

Sensitivity Analyses. We performed several sensitivity analyses to challenge the robustness of our results.

We considered exposure to BZDs not in terms of cDDD/d, but as binary variable exposed/unexposed, fixed at baseline (same time-window of interest as the main analysis) in a multivariate Cox model adjusted for the same covariates as the main analysis, and studied the association between BZDs exposure and THR survivorship in each stratum of age (3 groups), sex (male/female), exposure to antidepressants (Yes/No) and activity sector (public/private). As exposure to BZDs may vary over time, especially after THR, we considered exposure to BZDs as binary time-dependent variable. History of BZDs exposure was estimated by combining drug prescriptions and time to dispensing data: more than 40 days between two consecutive deliveries being an unexposed period. HRs for revision related to exposure to BZDs were then assessed using univariate and multivariate Cox proportional hazards regression models adjusting for the same factors as the main analysis, except exposure to antidepressants, which here was also treated as time-dependent binary variable. To complete these analyses with time-dependent exposure to BZDs, we estimated and described mean cDDD/d over time during follow-up in exposed patients.

We assessed anxiolytic-BZDs and hypnotic-BZDs exposure separately, within 6 months before or after inclusion. HRs for revision following anxiolytic-BZDs alone, hypnotic-BZDs alone and both anxiolytic- and hypnotic-BZDs were assessed using univariate and multivariate Cox proportional hazards regression models. Diazepam, oxazepam, clorazepate, chlordiazepoxide, clonazepam, bromazepam, clobazam, lorazepam, alprazolam, loflazepate and clotiapam as anxiolytic-BZDs and nitrazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, midazolam, loprazolam, Zopiclone and Zolpidem as hypnotic-BZDs.

Statistical tests were 2-tailed with 5% alpha-risk and analyses were performed using SAS Base 9.4 and SAS Enterprise Guide 4.3 software (SAS Institute Inc).
Results
Baseline
Mean age was 69.9 years (Standard Deviation, SD: 10.8). Women (57.9% of enrolled individuals) were significantly older than men (71.6 vs. 67.5, P < .0001). Implantation was performed in a private hospital in 65.7% of cases and nearly half of patients were implanted in centres performing 14 to 38 monthly procedures (Table 1). Median hospital stay was 8 days (interquartile range, IQR: 7–10). Fixation was uncemented: 73.0%, cemented: 6.1%, hybrid: 19.2% and reverse hybrid: 1.6%. Bearing surfaces were CoC: 40.7%, MoP: 34.0%, CoP: 21.0% and MoM: 3.3%. Regarding comorbidities, 9.4% were obese, 5% had dementia and 2.5% Parkinson’s disease. Regarding treatments, 18.6% were exposed to antidepressants (significant difference between men and women, 11.7% vs. 23.6%, P < .0001), 27.9% to oral corticosteroids, 8.1% to antiepileptic drugs (non-BZD) and 12.9% to anxiolytic or hypnotic drugs, non-BZD.

In our population, 48.3% of subjects were exposed to BZDs (15.7% highly exposed): 17.5% were exposed to anxiolytic-BZDs, 14.8% to hypnotic-BZDs, 9.8% to both anxiolytic and hypnotic-BZDs and 6.2% to other BZDs, such as an antiepileptics or muscle relaxants. Exposed patients received a mean cDDD/d of 0.40; they received an average 5.4 BZDs deliveries within the year around inclusion.

Baseline Characteristics according to BZDs exposure level
Table 2 shows baseline patient, hospital stay and THR characteristics according to cDDD/d group. Women and elderly patients were more exposed to BZDs than men and younger patients, respectively. Among exposed patients, median age was 72 years (IQR: 63–79) and 64.8% were women, and it was 70 years (IQR: 62–78) and 51.3% respectively among unexposed subjects. Patients with Parkinson’s disease were more often exposed to BZDs (27.3% high cDDD/d) than patients without this condition. We did not find major differences in BZDs exposure between diabetics / non-diabetics and obese / non-obese subjects. Patients taking antidepressants, antipsychotics, antiepileptics or anxiolytic/hypnotic non-BZD were more often exposed to BZDs: 77.8% of patients taking antidepressants were exposed to BZDs (39.2% highly exposed) versus 41.5% of patients not taking antidepressants (10.3% highly exposed). Patients staying longer in hospital after THR had higher BZDs exposure.

Revision and BZDs exposure relationship
During 45 months follow-up (IQR: 33–58; range: 0.03–72), 9,043 prosthetic revisions (3.7%) were recorded. Univariate survival analysis showed exposure to BZDs to be associated with a significant increase in revision risk compared with unexposed patients, with a dose-response relationship (cumulative revision rates: 3.0% in unexposed, 3.9% in low doses, 4.4% in medium doses and 4.8% in high doses of BZDs) (Fig 2). Univariate and Multivariate analyses gave similar results: adjusted HR, aHR = 1.18 (95%CI: 1.12–1.26) for low cDDD/d, aHR = 1.32 (95%CI: 1.24–1.40) for medium cDDD/d and aHR = 1.37 (95%CI: 1.29–1.45) for high cDDD/d, compared to unexposed patients. (Table 3).

In univariate and multivariate Cox proportional hazards regression analyses, prosthetic survivorship was also significantly associated with sex, age, obesity: female and older patients having a better prosthetic prognosis than men and younger patients, respectively. Parkinson’s disease and exposure to antidepressant, oral corticosteroid, antiepileptic and anxiolytic or hypnotic non-BZD are risk factors for THR revision, as are uncemented prosthesis, MoM THR and long stay. Complete results are provided in S1A Table.
Table 1. Baseline Characteristics of enrolled patients, Hospital Stays and THR according to sex.

| Patient Characteristics | Total (n = 249,597) | Male (n = 105,150) | Female (n = 144,447) |
|-------------------------|---------------------|-------------------|---------------------|
| Sex                     | %                   | %                 | %                   |
| Male                    | 42.1                | 100.0             | 100.0               |
| Female                  | 57.9                |                   |                     |
| Age category, y         | %                   | %                 | %                   |
| 40–59                   | 17.7                | 23.7              | 13.3                |
| 60–74                   | 44.4                | 46.8              | 42.7                |
| ≥ 75                    | 37.9                | 29.5              | 44.0                |
| Comorbidities           | %                   | %                 | %                   |
| Diabetes mellitus       | 11.9                | 14.5              | 10.0                |
| Obesity                 | 9.4                 | 9.9               | 9.0                 |
| Parkinson's disease     | 2.5                 | 2.2               | 2.8                 |
| Immunodeficiency        | 1.4                 | 1.2               | 1.6                 |
| Cancer                  | 2.3                 | 2.5               | 2.1                 |
| Asthma or COPD          | 15.2                | 16.3              | 14.4                |
| Dementia                | 5.0                 | 2.8               | 6.6                 |
| Chronic kidney disease  | 1.2                 | 1.3               | 1.2                 |
| Treatments              | %                   | %                 | %                   |
| Antidepressant          | 18.6                | 11.7              | 23.6                |
| Antihypertensive        | 60.5                | 59.6              | 61.3                |
| Oral corticosteroid     | 27.9                | 25.2              | 29.8                |
| Antiosteoporotics       | 10.8                | 2.0               | 17.2                |
| Psychostimulant         | 0.8                 | 0.6               | 1.0                 |
| Antiepileptic (non-BZD) | 8.1                 | 7.3               | 8.8                 |
| Anxiolytic/Hypnotic (non-BZD) | 12.9 | 10.9 | 14.4 |
| Antipsychotic           | 4.0                 | 3.8               | 4.1                 |
| Center and Hospital stay Characteristics | % | % | % |
| Activity sector         | %                   | %                 | %                   |
| Public                  | 34.3                | 34.3              | 34.4                |
| Private                 | 65.7                | 65.7              | 65.6                |
| No. of procedures per month | % | % | % |
| < 14                    | 25.1                | 25.2              | 25.1                |
| 14–38                   | 49.9                | 50.3              | 49.6                |
| > 38                    | 25.0                | 24.6              | 25.4                |
| Hospital stay Duration (days) | % | % | % |
| <6                      | 5.7                 | 6.9               | 4.9                 |
| 6–12                    | 84.2                | 84.5              | 84.0                |
| >12                     | 10.1                | 8.6               | 11.1                |
| THR Characteristics     | %                   | %                 | %                   |
| THR Cement Type         | %                   | %                 | %                   |
| Uncemented              | 73.0                | 78.6              | 69.0                |
| Cemented                | 6.1                 | 4.4               | 7.4                 |
| Hybrid                  | 19.2                | 15.9              | 21.6                |
| Reverse Hybrid          | 1.6                 | 1.1               | 2.0                 |
| THR bearing surface     | %                   | %                 | %                   |
| CoC                     | 40.7                | 46.8              | 36.3                |
| CoP                     | 21.0                | 20.0              | 21.7                |
| MoM                     | 3.3                 | 4.4               | 2.5                 |
| MoP                     | 34.0                | 28.0              | 38.4                |
| Unspecified             | 1.1                 | 0.9               | 1.2                 |

Abbreviations: CoC, ceramic-on-ceramic; CoP, ceramic-on-polyethylene; MoM, metal-on-metal; MoP, metal-on-polyethylene; THR, total hip replacement.

doi:10.1371/journal.pone.0155783.t001
### Table 2. Characteristics of the patients, centers, hospitals Stays and THR, according to exposure to BZDs.

| Patient Characteristics       | Unexposed, % | Exposed, % |
|------------------------------|--------------|-----------|
|                              | (n = 127 797) | Low (n = 41 196) | Medium (n = 39 181) | High (n = 38 766) |
| Sex                          | Male 59.7 16.5 12.8 11.0 | Female 45.9 16.8 18.1 19.1 |
|                             | Low Medium High | Low Medium High |
| Age category, y              | 40–59 53.2 19.2 14.3 13.4 | 60–74 53.5 17.1 14.8 14.6 |
|                             | ≥ 75 49.0 15.0 17.9 18.1 |
| Comorbidities                | Diabes mellitus No 51.9 16.9 16.0 15.3 | Yes 50.8 15.4 15.1 18.7 |
|                             | Obesity No 51.8 16.8 16.0 15.5 | Yes 51.7 16.0 14.7 17.6 |
|                             | Parkinson's disease No 52.2 16.7 15.8 15.4 | Yes 35.7 16.5 20.3 27.6 |
|                             | Immunodeficiency No 51.8 16.7 15.9 15.7 | Yes 49.0 17.0 17.2 16.9 |
|                             | Chronic kidney disease No 51.8 16.7 15.8 15.6 | Yes 47.4 14.8 17.7 20.1 |
| Treatments                   | Antidepressant No 58.5 17.2 13.9 10.3 | Yes 22.2 14.3 24.3 39.2 |
|                             | Antihypertensive No 56.1 18.1 14.2 11.6 | Yes 48.9 15.8 17.0 18.4 |
|                             | Oral corticosteroid No 55.6 15.7 14.6 14.2 | Yes 41.9 19.3 19.2 19.7 |
|                             | Antioseporotics No 53.0 16.6 15.4 15.0 | Yes 41.6 17.2 20.0 21.2 |
|                             | Psychostimulant No 51.9 16.7 15.8 15.6 | Yes 38.4 16.7 19.2 25.7 |
|                             | Antiepileptic (non-BZD) No 53.3 16.5 15.4 14.5 | Yes 31.6 18.5 20.8 29.1 |
|                             | Anxiolytic/Hypnotic (non-BZD) No 54.6 16.4 15.1 13.9 | Yes 32.5 18.4 20.9 28.2 |
|                             | Antipsychotic No 52.9 16.9 15.7 14.5 | Yes 25.3 11.8 19.1 43.8 |
| Center and hospital stay characteristics | Activity sector Public 50.8 16.4 16.1 16.6 | Private 52.2 16.8 15.7 15.2 |
|                             | No. of procedures per month < 14 50.5 16.5 16.5 16.6 | 14–38 51.9 16.6 15.7 15.8 |
|                             | ≥ 38 52.8 17.1 15.5 14.6 |
|                             | Duration in days < 6 59.9 16.0 12.9 11.3 | 6–12 52.1 16.8 15.7 15.4 |
|                             | ≥ 12 44.2 15.7 19.2 20.9 |
| THR Characteristics          | THR Cement Type Uncemented 52.7 16.8 15.4 15.1 | Cemented 48.1 16.2 17.9 17.8 |

(Continued)
No significant cDDD/d and sex or age interactions were detected in the relationship with prosthetic survivorship.

**Sensitivity Analyses**

The first sensitivity analysis showed aHR for BZDs-exposed patients at baseline, compared to unexposed to be consistent with the main analysis: 1.25 (95%CI: 1.19–1.31), as were results for stratified analyses on sex, age, exposure to antidepressants and activity: aHRs range 1.22 to 1.27. Sensitivity analysis results with BZDs exposure and exposure to antidepressant drugs as

![Image](https://example.com/image.png)

Patients at risk are given at baseline and yearly in the first 5 years. At the maximum follow-up time of 72 months, there were 5192 patients at risk.

**Fig 2. Kaplan Meier Cumulative Revision Risk According to Level of Exposure to BZDs.**

doi:10.1371/journal.pone.0155783.g002
time-dependant variables were also consistent with the main analysis results: aHR 1.29 (95% IC: 1.23–1.36) for BZDs-exposed patients, versus unexposed (Table 4). During follow-up, cDDD/d was 0.37 for over-time exposed patients; they received 4.2 BZDs average yearly deliveries.

When assessing separately baseline exposure to anxiolytic-BZDs alone, exposure to hypnotic-BZDs alone and exposure to both BZDs, aHR was 1.23 (95%IC: 1.16–1.30) for

Table 3. Associations between exposure level to BZDs and prosthetic revision.

|                | Revisions (n = 9043) | Univariate Cox Model (N = 246 940) | Multivariate Cox Model (N = 246 940) |
|----------------|----------------------|-----------------------------------|-------------------------------------|
|                | N                    | %                                 | Crude HR (IC 95%) p-value           | Adjusted HR§ (IC 95%) p-value             |
| Unexposed      | 127797               | 3.0                               | ref                                 | ref                                      |
| Low            | 41196                | 3.9                               | 1.26 (1.19–1.34)  <0.0001           | 1.18 (1.12–1.26) <0.0001                  |
| Medium         | 39181                | 4.4                               | 1.45 (1.37–1.53)  <0.0001           | 1.32 (1.24–1.40) <0.0001                  |
| High           | 38766                | 4.8                               | 1.63 (1.55–1.73)  <0.0001           | 1.37 (1.29–1.45) <0.0001                  |

§ Hazard Ratios were adjusted for: sex, age at implantation, diabetes mellitus, obesity, Parkinson's disease, immunodeficiency, exposure to antidepressant, oral corticosteroid, antosteoporotics, psychostimulant, antipsychotic, antiepileptic (non-BZD), anxiolytic or hypnotic (non-BZD), public or private sector, center volume of activity, duration of stay, cement type and bearing surface.

doi:10.1371/journal.pone.0155783.t003

Table 4. Sensitivity analyses–Stratified analyses (with exposure to BZDs studied as binary factor).

|                | No. of Patients | Adjusted HR§ (95% CI) | P Value |
|----------------|----------------|-----------------------|---------|
|                | Unexposed      | Exposed to BZDs       |         |
| Overall        | 246940         | 1 (ref)               | 1.29 (1.23–1.36) <0.0001  |
| Baseline (fixed) exposure to BZDs | 246940 | 1 (ref) | 1.25 (1.19–1.31) <0.0001  |
| Time-dependent exposure to BZDs | 246940 | 1 (ref) | 1.29 (1.23–1.36) <0.0001  |
| Analyses stratified on | | | |
| Sex            |                |                       |         |
| Male           | 104217         | 1 (ref)               | 1.24 (1.16–1.33) <0.0001  |
| Female         | 142723         | 1 (ref)               | 1.25 (1.18–1.33) <0.0001  |
| Age group      |                |                       |         |
| 40–59          | 43748          | 1 (ref)               | 1.27 (1.16–1.40) <0.0001  |
| 60–74          | 109991         | 1 (ref)               | 1.25 (1.17–1.34) <0.0001  |
| ≥ 75           | 93201          | 1 (ref)               | 1.22 (1.13–1.31) <0.0001  |
| Exposure to antidepressant |                |                       |         |
| No             | 201142         | 1 (ref)               | 1.24 (1.18–1.31) <0.0001  |
| Yes            | 45798          | 1 (ref)               | 1.25 (1.12–1.39) <0.0001  |
| Hospital sector |                |                       |         |
| Public         | 83925          | 1 (ref)               | 1.26 (1.16–1.35) <0.0001  |
| Private        | 163015         | 1 (ref)               | 1.24 (1.18–1.31) <0.0001  |
| Analyses according to class of BZDs exposure at baseline | | | |
| Exposure to Anxiolytic BZDs only | 43128 | 1 (ref) | 1.23 (1.16–1.30) <0.0001  |
| Exposure to Hypnotic BZDs only | 36042 | 1 (ref) | 1.28 (1.21–1.36) <0.0001  |
| Exposure to both BZDs | 24163 | 1 (ref) | 1.37 (1.28–1.47) <0.0001  |
| Exposure to other class of BZDs | 16519 | 1 (ref) | 1.28 (1.18–1.39) <0.0001  |

§ Hazard Ratios were adjusted for: sex, age at implantation, diabetes mellitus, obesity, Parkinson's disease, immunodeficiency, exposure to antidepressant, oral corticosteroid, antosteoporotics, psychostimulant, antipsychotic, antiepileptic (non-BZD), anxiolytic or hypnotic (non-BZD), public or private sector, center activity, duration of stay, cement type and bearing surface, in multivariate Cox models.

doi:10.1371/journal.pone.0155783.t004
anxiolytic-BZDs, 1.28 (95%IC: 1.21–1.36) for hypnotic-BZDs and 1.37 (1.28–1.47) for both, \( p<0.0001 \).

**Discussion**

In this population-based study including all THRs performed in France because of arthritis, patients exposed to BZDs had a significantly poorer THR survivorship than unexposed patients, with dose-effect relationship, independently of other prosthetic revision risk factors. Similar findings were found when stratifying analyses on sex, on age group, on hospital sector or on exposure to antidepressant drugs, ensuring the robustness of our results. This association was seen regardless of BZDs category, with increased risk from concomitant anxiolytic-BZD and hypnotic-BZD use. To our knowledge, this is the first study which examined the association between THR revision risk and level of exposure to BZDs in a population-based cohort. Our conclusions may not apply to patients having THR for trauma or bone cancer, these being excluded from our study.

The event analyzed was short-term prosthetic revision, main indications for which are osteoarticular infection, dislocation and periprosthetic fracture [32, 33]. BZDs are not known to affect bone quality or growth, or to increase infection rate. A major known adverse effect of BZDs is oversedation, which includes symptoms such as drowsiness, poor concentration and vigilance, ataxia, dysarthria, diplopia, myasthenia, vertigo and mental confusion. In the elderly, oversedation is more marked and persistent: even when taken at night, even low-dose hypnotic sedatives may cause acute confusional states the next day (partly due to decreased metabolism); some authors have shown increased risk of falling in elderly [34, 35]. Previous works studying the association between BZDs and risk of hip fracture found BZDs exposure to be a risk factor: aHRs 1.2 to 1.4 [12, 36, 37]. Consequently, it seems reasonable to assume that in exposed patients, BZDs may increase the risk of falls, possibly leading to THR fracture and revision; it is our hypothesis. Nonetheless, we were unable to identify direct causes for revision; studies covering both BZDs exposure and indications for revision would be necessary to investigate a possible underlying mechanism.

In our study, we measured baseline BZDs exposure in terms of cDDD/d. The DDD was first constructed as a technical measure to estimate specific drug consumption per capita, based on aggregate sales data records. It is nonetheless an internationally recognized measure which enables dosage comparisons between drug categories, making it the first choice for comparing prevalence of use and doses, over time and between areas [15,18,38]. Our assessment of baseline BZDs exposure as fixed factor in the main analysis could also be discussed, as exposure may vary overtime, especially after THR. However, estimated mean cDDD/d for patients exposed at baseline was very close to that of patients exposed during follow-up: cDDD/d were 0.40 and 0.37 respectively. We also compared the average number of times BZDs were dispensed within a year both for patients exposed at baseline and during follow-up: they respectively received BZDs 5 and 4 times yearly on average. This suggests a similar pattern in baseline exposure to BZDs and exposure to BZDs during follow-up. We also conducted sensitivity analyses where BZDs exposure was a fixed binary variable and then binary time-dependent variable; the results were both similar to those of the main analysis.

Regarding the proportion of BZDs-exposed patients, our results are consistent with data available for the elderly French population [11, 39–41], with almost every other patient over 70 being exposed. Similarly, we found that 64.8% of patients exposed were women compared to 64.2% in the last report by the French National Agency for Medicines and Health Products Safety [41]. Average cDDD/d in exposed patients from our cohort was higher than that in the general French population. This is consistent with the fact that patients from our cohort had
arthritis, which causes pain, were older and mainly women; age and sex are known to be associated with exposure [11]. The 3.7% prosthetic revision rate at 45 months follow-up is consistent with data from international registries [32, 42–47]. Our results for the covariates studied also concord with previous findings which identify younger age [48–51], male sex [47,48], obesity [52], uncemented prostheses [31,49], MoM THR [31] and long hospital stay as primary THR revision risk factors. Low surgeon activity volume was also cited as a risk factor for early revision [53,54]; we found the same with hospital volume activity as proxy of that of surgeons. Regarding oral corticosteroid exposure, our results are also consistent with literature: some studies found patients taking corticosteroids chronically at increased risk of readmission, implant failure and post-THR infection [55–60].

The large number of patients, the possibility of comparing prosthetic survivorship according to BZDs exposure in cDDD/d and of adjusting survival analysis for many known and suspected prosthetic revision risk factors in multivariate Cox models are strengths of the study. Like all studies using healthcare databases, exposure to treatment is derived from drug dispensing data instead of effective drug intake. However, the possible classification bias is non-differential and given that BZDs dispensations are regularly renewed overtime, it is reasonable to assume that the drug is ingested.

Due to missing THR characteristics, we excluded 2,657 individuals (1.1%) from the analyses. In this group, revision rate was 3.8% and BZDs exposure 51.6% which is comparable to those in the analyzed individuals. We do not think excluding these patients substantially affected the observed associations.

Implant survivorship may not be the only relevant outcome after THR. Although prosthetic revision is an unambiguous outcome, it is not the only sign of implant failure; considering revision as the only outcome in implant survivorship has been debated in orthopaedic literature. Other markers, including quality of life and/or functional improvement, could be used as secondary outcome to identify non-revised implant failure, but the SNIIRAM database does not provide such information. Although direct costs related to BZDs are not an economic priority [39], their misuse and/or overuse result in significant indirect costs which is not our topic, but could be assessed by dedicated medico economic studies. Lastly, despite the large number of covariates taken for adjustment in the multivariate Cox model, residual confounding due to factors not collected in our study (for being absent from the data base, such as smoking history, alcohol ingestion, socioeconomic factors or premorbid nutrition ...) cannot be ruled out.

Conclusion

People who are prescribed BZDs have a higher THR revision rate. Cautious prescribing might be needed as well as careful history examination and assessment of risk for patients with a hip prosthesis.

Supporting Information

S1 Table. Associations between characteristics of the patients, hospital stays and THR with Prosthetic Revision.

(DOCX)

Author Contributions

Conceived and designed the experiments: DB SC MZ. Performed the experiments: DB SC CC RDS MZ. Analyzed the data: DB SC CC RDS MZ. Contributed reagents/materials/analysis
tools: DB SC. Wrote the paper: DB SC MZ. Revision of the manuscript: DB SC CC RDS MZ. Study supervision: SC MZ.

References
1. Allen KD, Golightly YM. Epidemiology of osteoarthritis: state of the evidence. Curr Opin Rheumatol. 2015 May; 27 (3):276–83. doi: 10.1097/BOR.00000000000000161 PMID: 25775186
2. Song J, Chang RW, Dunlop DD. Population Impact of Arthritis on Disability in Older Adults. Arthritis Rheum. 2006 Apr 15; 55 (2):248–55. PMID: 16583415
3. McDonough CM, Jette AM. The contribution of osteoarthritis to functional limitations and disability. Clin Geriatr Med. 2010 Aug; 26 (3):387–99. doi: 10.1016/j.cger.2010.04.001 PMID: 20699161
4. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. The Lancet. 2007 Nov 2; 370 (9597):1508–19.
5. Pivec R, Johnson AJ, Mears SC, Mont MA. Hip arthroplasty. The Lancet. 2012 Nov 23; 380 (9855):1768–77.
6. Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2015 Jul 1;n/a–n/a.
7. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004 Feb; 57 (2):121–6. PMID: 14748810
8. Gallagher HC. Addressing the Issue of Chronic, Inappropriate Benzodiazepine Use: How Can Pharmacists Play a Role? Pharmacy. 2013 Sep 25; 1 (2):65–93.
9. Glass J, Lancot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005 Nov 19; 331 (7526):1169. PMID: 16284208
10. Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol (Oxf). 2007 Sep 1; 21 (7):774–82.
11. Rapport de l’Office Parlementaire d’Evaluation des Politiques de Santé (OPEPS): « Le bon usage des médicaments psychotropes ». N° 3187 (Assemblée Nationale) et N°422 (Sénat) [Internet]. 2006 Juin. Available: http://www.assemblee-nationale.fr/12/rap-off/i3187.asp. Accessed 15 November 2015.
12. Requena G, Huerta C, Gardarsdottir H, Logie J, González-González R, Abbing-Karahagopian V, et al. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. Pharmacoepidemiol Drug Saf. 2015 Jun 1;n/a–n/a.
13. Wagner AK, Zhang F, Soumerai SB, Walker AM, Gurwitz JH, Glynn RJ, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004 Jul 26; 164 (14):1567–72. PMID: 15277291
14. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995 Mar 23; 332 (12):767–73. PMID: 7862179
15. Bakken MS, Engeland A, Engesaeter LB, Randoff AH, Hunskaar S, Raths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol. 2014 Jul; 70 (7):873–80. doi: 10.1007/s00228-014-1684-2 PMID: 24810612
16. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Stürmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010 Dec; 19 (12):1248–55. doi: 10.1002/pds.2031 PMID: 20931664
17. Chang C-M, Wu EC-H, Chang I-S, Lin K-M. Benzodiazepine and risk of hip fractures in older people: a nested case-control study in Taiwan. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2008 Aug; 16 (8):686–92.
18. Vestergaard P, Rejmark L, Moskilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2006; 17 (6):807–16.
19. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001 Jun; 158 (6):892–8. PMID: 11384996
20. Herings RM, Stricker BH, de Boer A, Bakker A, Sturman F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995 Sep 11; 155 (16):1801–7. PMID: 7654115
21. Lichtenstein MJ, Griffin MR, Cornell JE, Malcolm E, Ray WA. Risk factors for hip fractures occurring in the hospital. Am J Epidemiol. 1994 Nov 1; 140 (9):830–8. PMID: 7977293
22. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987 Feb 12; 316 (7):363–9. PMID: 2880292
23. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989 Dec 15; 262 (23):3303–7. PMID: 2573741
24. Raguideau F, Mezzarobba M, Zureik M, Weill A, Ricordeau P, Alla F. Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. Pharmacoepidemiol Drug Saf. 2015 May; 24 (5):526–33. doi: 10.1002/pds.3763 PMID: 25753265
25. Fagot J-P, Blotière P-O, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care. 2013 Feb; 36 (2):294–301. doi: 10.2337/dc12-0506 PMID: 22966091
26. Romon I, Rey G, Mandereau-Bruno L, Weill A, Jougla E, Eschwège E, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes—the 2001–2006 ENTRED cohort. Diabet Med J Br Diabet Assoc. 2014 Aug; 31 (8):946–53.
27. Bouillon K, Bertrand M, Maura G, Blotière P-O, Ricordeau Zureik M. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015 Apr; 2 (4):e150–9. doi: 10.1016/S2352-3026(15)00027-7 PMID: 26687957
28. Tricotel A, Collin C, Zureik M. Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France. J Thromb Haemos JTH. 2015 Sep; 13 (9):1576–80. doi: 10.1111/jth.13053 PMID: 26179493
29. Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010 Mar; 19 (3):256–65. doi: 10.1002/pds.1912 PMID: 20128015
30. WHO. Collaborating Centre for Drugs Statistics Methodology. [Internet]. Available: http://www.whocc.no/. Accessed 12 July 2012.
31. Colas S, Collin C, Piriou P, Zureik M. Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship: A Population-Based Study. JAMA Surg. 2015 Oct 1; 150 (10):979–88. doi: 10.1001/jamasurg.2015.1325 PMID: 26288068
32. National Joint Registry. NJR 11th annual report 2014. [Internet]. Available: http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/11th_annual_report/NJR%2011th%20Annual%20Report%202014.pdf
33. Sibanda N, Copley LP, Lewsey JD, Borroff M, MacGregor AJ, et al. Revision rates after primary hip and knee replacement in England between 2003 and 2006. PlomS Med. 2008 Sep 30; 5 (9): e179. doi: 10.1371/journal.pmed.0050179 PMID: 18767900
34. Ashton H. Toxicity and adverse consequences of benzodiazepine use. Psychiatric Annals, Vol 25(3), Mar 1995, 158–165.
35. Uzun S. Side Effects Of Treatment With Benzodiazepines. Psychiatria Danubina, 2010; Vol. 22, No. 1, pp 90–93 PMID: 20305598
36. Xing D, Ma XL, Ma JX, Wang J, Yang Y, Chen Y. Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2014 Jan; 25 (1):105–20.
37. Khong TP, de Vries F, Goldberg JSB, Klungel OH, Robinson NJ, Ibáñez L, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int. 2012 Jul; 91 (1):24–31. doi: 10.1007/s00223-012-9603-8 PMID: 22566242
38. Egan MY, Wolfson C, Moride Y, Monette J. High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates. BMC Geriatr. 2001 Nov 23; 1 (1):4.
39. Bégaud B, Costagliola D. Rapport sur la surveillance et la promotion du bon usage du médicament en France [Internet]. 2013 Sep. Available: http://www.sante.gouv.fr/IMG/pdf/Rapport_Begaud_Costagliola.pdf
40. Haute Autorité de Santé. Améliorer la prescription des psychotropes chez le sujet âgé. 2007 Oct.
41. Agence Nationale de Sécurité du Médicament et des produits de santé. État des lieux de la consommation des benzodiazépines en France. 2013 Dec.
42. Australian Orthopaedic Association–National Joint Replacement Registry. Australian Orthopaedic Association–National Joint Replacement Registry: annual report 2014. [Internet]. Available: https://aoanjr.dmac.adelaide.edu.au/documents/10180/172286/Annual%20Report%202014
43. Canadian Institute for Health Information. Hip and knee replacements in Canada: Canadian Joint Replacement Registry 2014 Annual Report. [Internet]. Available: https://secure.cihi.ca/free_products/CJRR%202014%20Annual%20Report_EN-web.pdf

44. Centre of Excellence of Joint Replacements. Nasjonalt Register for Leddproteser: report June 2010. [Internet]. Available: http://nrlweb.ihelse.net/eng/Report_2010.pdf

45. Netherlands Orthopaedic Association. Insight into quality of orthopaedic care in the Netherlands—annual report of the Dutch Arthroplasty Register (Landelijke Registratie Orthopedische Implantaten). [Internet]. 2012. Available: http://www.lroi.nl/uploads/dd/hs/ddhsXrhkkSoA_vpBMBMKA/LROI-report-Executive-summary-Insight-into-quality-of-orthopaedic-care-in-the-Netherlands.pdf

46. New Zealand Joint Registry. The New Zealand Joint Registry—14-year report—January 1999 to December 2012. [Internet]. Available: http://www.nzoa.org.nz/system/files/NJR%2014%20Year%20Report.pdf

47. Swedish Hip Arthroplasty Register. Swedish Hip Arthroplasty Register annual report 2012. [Internet]. Available: http://www.sghr.se/en/Publications/DocumentsReports.aspx

48. Johansen SP, Sørensen HT, Lucht U, Seballe K, Overgaard S, Pedersen AB. Patient-related predictors of implant failure after primary total hip replacement in the initial, short- and long-terms. A nationwide Danish follow-up study including 36,984 patients. J Bone Joint Surg Br. 2006 Oct; 88 (10):1303–8. PMID: 17012418

49. Haier NP, Garelick G, Kårholm J. Uncemented and cemented primary total hip arthroplasty in the Swedish Hip Arthroplasty Register. Acta Orthop. 2010 Feb; 81 (1):34–41. doi: 10.3109/1745361003685400 PMID: 20180715

50. El Masri F, Kerboull L, Kerboull M, Courpied JP, Hamadouche M. Is the so-called “French paradox” a reality?: long-term survival and migration of the Charnley-Kerboull stem cemented line-to-line. J Bone Joint Surg Br. 2010 Mar; 92 (3):342–8. doi: 10.1302/0301-620X.92B3.23151 PMID: 20190303

51. Ong KL, Lau E, Suggs J, Kurtz SM, Manley MT. Risk of Subsequent Revision after Primary and Revision Total Joint Arthroplasty. Clin Orthop. 2010 Nov; 468 (11):3070–6. doi: 10.1007/s11999-010-1399-0 PMID: 20499292

52. Wright EA, Katz JN, Baron JA, Wright RJ, Malchau H, Mahomed N, et al. Risk factors for revision of primary total hip replacement: Results from a national case-control study. Arthritis Care Res. 2012 Dec; 64 (12):1879–85.

53. Paterson JM, Williams JI, Kreder HJ, Mahomed NN, Gunraj N, Wang X, et al. Provider volumes and early outcomes of primary total joint replacement in Ontario. Can J Surg J Can Chir. 2010 Jun; 53 (3):175–83.

54. Fender D, Meulen JHP van der, Gregg PJ. Relationship between outcome and annual surgical experience for the Charnley total hip replacement RESULTS FROM A REGIONAL HIP REGISTER. J Bone Joint Surg Br. 2003 Mar 1; 85-B (2):187–90.

55. Boylan MR, Perfetti DC, Elmallah RK, Krebs VE, Paulino CB, Mont MA. Does Chronic Corticosteroid Use Increase Risks of Readmission, Thromboembolism, and Revision After THA? Clin Orthop. 2015 Nov 9;

56. Cordero-Ampuero J, de Dios M. What are the risk factors for infection in hemiarthroplasties and total hip arthroplasties? Clin Orthop. 2010 Dec; 468 (12):3268–77. doi: 10.1007/s11999-010-1411-8 PMID: 20544319

57. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatol Oxf Engl. 2010 Feb; 49 (2):341–7.

58. Malviya A, Walker LC, Avery P, Osborne S, Weir DJ, Foster HE, et al. The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate. J Bone Joint Surg Br. 2011 Apr; 93 (4):443–8. doi: 10.1302/0301-620X.93B4.26078 PMID: 21464480

59. Mednick RE, Alvi HM, Krishnan V, Lovecchio F, Manning DW. Factors Affecting Readmission Rates Following Primary Total Hip Arthroplasty. J Bone Joint Surg Am. 2014 Jul 16; 96 (14):1201–9. PMID: 25031375

60. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013 Nov 29; 7:119–24. doi: 10.2174/18743129201312100005 PMID: 24454587